Enter your keywords
HOME
About Us
NEWSLETTER
To search AlzRisk, use the "Keyword" search on the
AlzRisk search page
.
NEWS
All News
Conference Coverage
Series
WEBINARS
All Webinars
Databases
AlzBiomarker
AlzPedia
AlzRisk
Antibodies
Genetics
AlzGene
HEX
Mutations
Protocols
Research Models
Therapeutics
PAPERS
All Papers
Papers of the Week
Milestone
Alzforum Recommends
PROFESSIONAL RESOURCES
Conference Calendar
Grants
Jobs
Member Directory
ABOUT AD
AD Overview
Early-Onset Familial
The HBO Alzheimer's Project
Supported Browsers
MY ALZFORUM
My AlzForum Home
View Library
View Notifications
Set Notifications
Edit Profile
AlzRisk Paper Detail
Risk Factors
Alcohol
B Vitamins
Blood Pressure
Cognitive Activity
Diabetes Mellitus
Dietary Pattern
Head injury
Homocysteine
Hormone Therapy
Inflammatory Biomarkers
Non-Steroidal Anti-Inflammatory Drugs
Nutritional Antioxidants
Obesity
Physical Activity
Statin use
Reference:
Li, 2010
Cohort:
Adult Changes in Thought-Group Health Cooperative
Risk Factor:
Statin use
Exposure Detail
The interviewers ascertained exposure data from computerized pharmacy records, which included information on drug, dosage, quantity dispensed, prescription date, and instructions.
"GHC patients receive prescriptions through the GHC pharmacy at no or nominal cost. The GHC pharmacy database was established in January 1977. Its data files contain information on drug, dosage, quantity dispensed, prescription date, and instructions. Use of statin medications (simvastatin, lovastatin, pravastatin, and atorvastatin) and other lipid-lowering agents (LLAs), including niacin,cholestyramine, colestipol, gemfibrozil, and clofibrate, was defined as at least three filled prescriptions for statins or LLAs of 15 tablets or more. Subjects who did not use statins consistently with average daily dose (cumulative dose/duration <0.5 and total number of refills <12) were considered nonusers. To quantify statin use, an approximation of one ‘‘statin equivalent dose’’ of 10mg of simvastatin, 20mg of lovastatin or pravastatin, or 5mg of atorvastatin was used. Duration of statin use was defined as the time elapsed from the date of first statin prescription to the date of last prescription."
The investigators compared incident AD risk in two groups: the group of participants who used statins, as defined above ("Used") and the reference group of participants who did not use statins consistently, also as defined above ("Did not use").
Screening and Diagnosis Detail
Screening Method:
CASI
Cognitive Abilities Screening Instrument (Teng 1994)
Neuropsych Testing
Other
AD Diagnosis:
DSM IV
Diagnostic and Statistical Manual IV
NINCDS ADRDA
National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association Criteria (McKhann 1984)
Total Dementia Definition:
Dementia via DSM-IV clinical criteria
"After enrollment, participants were re-screened every 2 years using the CASI. Those whose CASI scores were lower than 86 underwent a standardized dementia diagnostic evaluation that included examination by a study physician and neuropsychological tests. Relevant laboratory tests and neuroimaging studies were performed, or results were obtained from GHC records. Diagnoses were assigned at consensus diagnostic conferences using Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, criteria for dementia and National Institute of Neurological and Communicative Disorders and Stroke Alzheimer Disease and Related Disorders Association (NINCDS-ADRDA) criteria for AD. Those with new-onset dementia underwent at least one annual follow-up examination for verification of dementia status and subtype. Dementia onset was defined according to convention as halfway between the date of diagnosis and the date of the prior ACT study examination that showed no dementia."
Covariates & Analysis Detail
Analysis Type:
Cox proportional hazards regression
Researchers stratified the analysis by five-year categories of age and by APOE-e4 status. Age was used as the time-scale
AD Covariates:
A
age
E
education
G
gender
APOE4
APOE e4 genotype
CASI
baseline CASI score
BMI
body mass index
CHRT
cohort
CMVD
comorbid vascular disease
LLA
other lipid lowering agent use
RE
race/ethnicity
SM
smoking status